Rodman & Renshaw analyst Tony Butler initiated coverage of Leap Therapeutics with a Buy rating and $8 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LPTX:
- Leap Therapeutics price target lowered to $5.50 from $7 at H.C. Wainwright
- Leap Therapeutics reports Q1 EPS (51c), consensus (58c)
- Leap Therapeutics Reports First Quarter 2024 Financial Results
- LPTX Earnings this Week: How Will it Perform?
- Leap Therapeutics files to sell 14.18M shares of common stock for holders